GEN-MKT-18-7897-A
Apr 29, 2026 | Biopharma, Blogs | 0 comments
Differentiation of Leu and Ile residues using EAD. EAD can lead to secondary fragmentation of the side chains of Leu and Ile residues in the z ions, producing signature w ions (z-29 and z-43) from the neutral loss of C3H7 (43 Da) for Leu and C2H5 (29 Da) for Ile. The detection of these diagnostic fragments enables unambiguous differentiation of Leu vs. Ile.
EAD spectrum of a low-abundant V→Xle (Xle=Lue or Ile) sequence variant (<0.05%) of the VVSV peptide in NISTmAb. The detection of a z13-29 (w13) ion in this EAD spectrum shows that the Xle residue is an Ile instead of a Leu.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network